Let’s start up with the current stock price of Intellia Therapeutics Inc. (NTLA), which is $83.15 to be very precise. The Stock rose vividly during the last session to $84.41 after opening rate of $80.27 while the lowest price it went was recorded $79.19 before closing at $80.43.
Recently in News on June 4, 2021, Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting. Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate. You can read further details here
Intellia Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $92.00 on 01/15/21, with the lowest value was $43.86 for the same time period, recorded on 03/05/21.
Intellia Therapeutics Inc. (NTLA) full year performance was 303.44%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Intellia Therapeutics Inc. shares are logging -9.62% during the 52-week period from high price, and 402.72% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $16.54 and $92.00.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1018798 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Intellia Therapeutics Inc. (NTLA) recorded performance in the market was 52.85%, having the revenues showcasing 26.04% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 5.61B, as it employees total of 312 workers.
Market experts do have their say about Intellia Therapeutics Inc. (NTLA)
During the last month, 10 analysts gave the Intellia Therapeutics Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 4 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 69.13, with a change in the price was noted +1.26. In a similar fashion, Intellia Therapeutics Inc. posted a movement of +1.54% for the period of last 100 days, recording 1,407,749 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for NTLA is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Intellia Therapeutics Inc. (NTLA)
Raw Stochastic average of Intellia Therapeutics Inc. in the period of last 50 days is set at 85.46%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 95.13%. In the last 20 days, the company’s Stochastic %K was 92.66% and its Stochastic %D was recorded 89.93%.
Bearing in mind the latest performance of Intellia Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 52.85%. Additionally, trading for the stock in the period of the last six months notably improved by 75.94%, alongside a boost of 303.44% for the period of the last 12 months. The shares increased approximately by 16.28% in the 7-day charts and went down by 25.66% in the period of the last 30 days. Common stock shares were driven by 26.04% during last recorded quarter.